Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1481111

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1481111

Glaucoma Therapeutics

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Glaucoma Therapeutics Market to Reach $7.2 Billion by 2030

The global market for Glaucoma Therapeutics estimated at US$5.7 Billion in the year 2023, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Combination Drugs segment is estimated at 4.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 5.5% CAGR

The Glaucoma Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.9% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$930.1 Million by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 44 Featured) -

  • Aerie Pharmaceuticals, Inc.
  • Allergan, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Valeant Pharmaceuticals International, Inc.
Show more
Product Code: MCP16433

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Glaucoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glaucoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glaucoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Prostaglandins Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Prostaglandins Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Prostaglandins Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Alpha Adrenergic Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Alpha Adrenergic Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Alpha Adrenergic Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Carbonic Anhydrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Carbonic Anhydrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Carbonic Anhydrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • JAPAN
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • CHINA
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • EUROPE
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Glaucoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • FRANCE
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • GERMANY
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Glaucoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • INDIA
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Glaucoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Glaucoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • AFRICA
    • Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!